Henry Schein Partnering With France’s Biotech Dental Group

Health care solutions provider Henry Schein, Inc., has completed the acquisition of a majority ownership stake of Biotech Dental S.A.S., a rapidly growing provider of dental implants, clear aligners, and innovative digital dental software based in Salon-de-Provence, France.

Biotech Dental has several important solutions, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience, according to a press release this week. The transaction was announced on December 16, 2022.

Biotech Dental is also one of the fastest-growing manufacturers in France of custom abutments and implants, under the Kontact™ brand, and of clear aligners, under the Smilers brand. In addition, the French company has launched LaGalaxy , a comprehensive, open, and secure software platform where both clinical and administrative tasks can be performed. Within a single platform, dentists and dental laboratories benefit from end-to-end integrated digital solutions that help improve case outcomes while speeding treatment time, shortening case completion, and lowering the costs of implants, orthodontic, and prosthetic treatments. Henry Schein and Biotech Dental state they are mutually invested in the growth of these businesses and the Biotech Dental brand globally.

“We at Henry Schein welcome our new Biotech Dental colleagues and are most excited about the opportunity to bring Biotech Dental’s software products to our customers,” says Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Together with our existing portfolio of software products, Henry Schein and Biotech Dental will create a digital workflow that provides a seamless journey for our customers to increase case acceptance and improve clinical outcomes for practitioners.”

The integration of Biotech Dental’s software with Henry Schein One’s practice management software solutions is designed to help customers streamline their clinical as well as administrative workflow for the ultimate benefit of patients.

“We are also very enthusiastic to partner with Biotech Dental to advance the global adoption of their outstanding product portfolio of implants and our combined portfolio of clear aligners and clinical workflow software,” Bergman adds.

Philippe Veran, Biotech Dental Founder and President, will continue to lead the business, supported by Dr. Olivia Veran, a dental surgeon who is Biotech Dental's Senior Vice President and Managing Director. Biotech Dental will maintain its own brands and go-to-market strategies. Dr Veran will work closely with Henry Schein’s management team to advance the growth of the company’s software, implant, and orthodontics businesses globally.

As part of the transaction, Philippe Veran and Dr Veran will also become minority partners in Henry Schein Orthodontics. This alignment enables the 2 companies to offer a comprehensive set of orthodontic solutions to its combined customer base, including software, aligners, and traditional orthodontic appliances.

“We are very pleased to complete our partnership with Henry Schein, a company that shares our commitment to provide dentists, orthodontists, and dental laboratories with the specialized tools they need to provide quality care to their patients,” says Philippe Veran. “This investment marks a new chapter for our customers, who will benefit from the innovation and new technologies we will bring to the global dental community as well as access to a wide array of products and services available through Henry Schein.”

Under the terms of the transaction, Henry Schein acquired a majority ownership position in Biotech Dental. Upperside Capital Partners Group will continue to own the remaining minority interest in the company. For the fiscal year 2022, Biotech Dental’s revenue was approximately $100 million. Henry Schein expects this transaction to be slightly dilutive to 2023 earnings per share when excluding amortization expense primarily due to non-cash acquisition accounting adjustments for inventory. Financial terms were not disclosed.